The annual societal cost of Parkinson's disease across Europe reached €22.8 billion in 2019 according to a new study within the EAN-led Cost of Illness in Neurology in Europe (COIN-Eu) initiative.
Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Prevalence of mental disorders, suicidal ideation and suicides in the general population before and during the COVID-19 pandemic in Norway: A population-based repeated cross-sectional analysis